Scarica l'app Stockscreener
5.78
4.52%
0.25
Dopo l'orario di chiusura:
5.78
Precedente Chiudi:
$5.53
Aprire:
$5.4
Volume 24 ore:
647.09K
Relative Volume:
0.65
Capitalizzazione di mercato:
$392.78M
Reddito:
-
Utile/perdita netta:
$-119.87M
Rapporto P/E:
-3.1934
EPS:
-1.81
Flusso di cassa netto:
$-109.90M
1 W Prestazione:
-1.20%
1M Prestazione:
-28.02%
6M Prestazione:
-40.96%
1 anno Prestazione:
-52.51%
Intervallo 1D:
$5.32
$5.98
Intervallo di 1 settimana:
$5.25
$6.38
Portata 52W:
$5.25
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Confronta ORIC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
5.78 | 392.78M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
NEOS Investment Management LLC Purchases Shares of 45,476 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Brokerages - MarketBeat
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan
Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa
ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia
PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire
Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World
(ORIC) Investment Report - news.stocktradersdaily.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat
(ORIC) Investment Analysis and Advice - news.stocktradersdaily.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks
ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire
Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan
Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):